|
Страница 5 из 6 Наконец, в отличие от всех других антигипертензивных препаратов моксонидин способен уменьшать инсулинорезистентность у больных сахарным диабетом 2 типа. Дальнейшее расширение показаний к использованию препаратов данной группы требует проведения крупномасштабных многоцентровых исследований, которые должны дать ответ на вопрос: как влияет длительное применение агонистов имидазолиновых рецепторов на выживаемость пациентов с АГ и риск основных сердечно-сосудистых исходов.
Литература
Ernsberger P, Damon TH, Graff LM, et al. Moxonidine, a centrally acting anti-hypertensive agent, is a selective ligand for Il-imidazoline sites. J Pharmacol Exp Ther 1993;264:172-82. Gothert M, Brass M, Bonisch H, Molderings GJ. Presynaptic Imidazoline Receptors: New Developments in Characterization and Classification. Ann NY AcadScil999;881:99-143. Ernsberger P. The II-Imidazoline Receptor and Its Cellular Signaling Pathways. ArmNYAcadSci 1999;881:35-53. Timmermans P, van Zwieten PA. a-Adrenoreceptors: Classification, localization, mechanisms, and target for drags. J Med Chem 1982;25:1389-1401. van Zwieten H. Modulation of sympathetic outflow by centrally acting antihyper-tensive drags. Cardiovasc Drags Ther 1996;10:283-9. Harron D. Clinical pharmacology of imidazolines and related compounds. Fundam Clin. Pharmacol 1992;6:S41-4. Chan CK, Head GA. Relative importance of central imidazoline receptors for antihypertensive effects of moxonidine and rilmenidine. J Hypertens 1996;14:855-64. Menani JY, Sato MA, Haikel L, et al Central moxonidine on water and NaCl intake. Brain Res Bull 1999;49:273-9. Cechetto DF, Kline RL. Effect of rilmenidine on arterial pressure and urinary output in the spontaneously hypertensive rat. Eur J Pharmacol 1997;325:47-55. Mukaddam-Daher S, Gutkowska J. Atrial natriuretic peptide is involved in renal action of moxonidine. Hypertension 2000;35:1215-20. Amann K, Nichols C, Tornig J, et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996;11:1003-11. Haxhiu MA, Dreshaj IA, McFadden CB, et al. Moxonidine acting centrally inhibits airway reflex responses. Ann NY Acad. Sci 1999;881:372-82. Bing C, King P, Pickavance L, et al. The effect of moxonidine of feeding and body fat in obese Zucker rats; role of hypothalamic NPY neurons. Br J Pharmacol 1999; 127:35-42. Troconiz IF, de Alwis DP, Tillmann C, et al. Comparison of manual versus ambulatory blood pressure measurements with pharmacocinetic-pharmacodinamic modeling of antihypertensive compounds: application on moxonidine. Clin Pharmacol Ther 2000;68:18-27. Messerli F. Moxonidine: a new and versatile antihypertensive. J Cardiovasc Pharmacol 2000;35:S53-6. Genissel P, Bromet N. Pharmacokinetics of rilmenidine Am J Med 1989;87:S18-23. Szabo B, Bock C, Nordheim U, et al. Mechnism of the sympaticoinhibition produced by the clonidine-like drags rilmenidine and moxonidine. Ann NY Acad Sci 1999;881:253-64. Mitrovic V, Patyna W, Huting Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. J Cardiovasc Drag Ther 1991;5:967-72. Trimarco B, Morisco C, Sarno D, et al. Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass. J Cardiovasc Pharmacol 1995;26(S2):29-33. Bamberger CM, Monig H, Mill G, et al. Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH. Exp Clin Endocrinol Diabetes 1995;103:205-8. Prichard BN, Graham BR. Effective antihypertensive therapy: blood pressure control with moxonidine. J Cardiovasc Pharmacol 1996;27(S3):38-48. Sadowski Z, Szwed H, Kuch-Wocial A, et al. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study. J Hypertens 1998;16:55-62 Dikstein K, Manhenke C, Aarsland T, et al. The effect of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure. Int J Cardiol2000;75:167-76. Dickstein K, Manhenke C, Aarsland T, et al. Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 1999;83:1638-44. Coats A. Heart Failure 99 - the MOXCON story. Int J Cardiol 1999;71:109-11. Strojek K, Grzeszczak W, Gorska J, et al. Lowering of microalbuminuria in diabetic patients by sympaticoplegic agent: novel approach to prevent progression of diabetic nephropathy. (Читайте продолжение)
|
